TABLE 2.
Approaches | Bioactive ligands/transmembrane proteins | Methods | References |
Direct modification | |||
Bioconjugation reaction | CP05 | Directly bind to the second extracellular loop of CD63 | Gao et al., 2018 |
RGE-peptide | Cycloaddition reaction | Jia et al., 2018 | |
BMSC-specific aptamer | Schiff base reaction | Luo et al., 2019 | |
Hydrophobic insertion | RGD peptide | Incubated in modified medium containing DSPE-PEG-RGD | Wang et al., 2017 |
Genetic engineering | |||
Non-specific proteins | Lamp2b | T7 | Kim et al., 2020 |
RAGE-binding peptide | Kim et al., 2021 | ||
tLyp-1-lamp2b | Bai et al., 2020 | ||
HuR | Li Z. et al., 2020 | ||
The tetraspanin superfamily | CD9 | Li et al., 2019 | |
The 2nd extracellular loop of CD63 | Duong et al., 2019 | ||
CD63-VEGFC fusion protein | Li B. et al., 2020 | ||
CD63 truncations | Curley et al., 2020 | ||
Receptor membrane proteins | PDGFR | Human CD3 and HER2 receptors | Shi et al., 2020 |
GPI | Anti-EGFR nanobodies | Kooijmans et al., 2016a | |
HER2 | DARPin G3 | Molavipordanjani et al., 2020 | |
C1C2 domain of lactadherin | RGD-4C peptide | Tian et al., 2021 | |
Ag | Bliss et al., 2020 |